HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 8, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced
-- Azeliragon is the only RAGE receptor antagonist in clinical development for Alzheimer’s Disease -- HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 1, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced the completion of enrollment for vTv’s Phase 3 placebo-controlled trial, STEADFAST
HIGH POINT, N.C. --(BUSINESS WIRE)--May 3, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, among other therapeutic areas, today provided
HIGH POINT, N.C. --(BUSINESS WIRE)--Mar. 10, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, among other therapeutic areas, today
Completed enrollment of Part A pivotal Phase 3 STEADFAST Study of azeliragon in Alzheimer’s Disease Positive Phase 2 results for Type 2 diabetes therapies, TTP273 and TTP399 HIGH POINT, N.C. --(BUSINESS WIRE)--Feb. 27, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage
Oral small molecule GLP-1 receptor agonist met primary endpoint Company’s second successful Phase 2 diabetes trial in 2016 HIGH POINT, N.C. --(BUSINESS WIRE)--Dec. 14, 2016-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced positive data from its Phase 2 study evaluating TTP273, an oral
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 16, 2016-- vTv Therapeutics Inc. (vTv, Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered small molecule drug candidates to fill significant unmet medical needs, today announced that
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 10, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will be participating in
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 2, 2016-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today provided a corporate update and
HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 24, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that the company’s Chief